The interface between publicly funded and industry-funded research in pediatric psychopharmacology: Opportunities for integration and collaboration

Biological Psychiatry

Volumn 56, Issue 1, 2004, Pages 3-9

  Vitiello, Benedetto ^a   Heiligenstein, John H ^b   Riddle, Mark A ^c   Greenhill, Laurence L ^d   Fegert, Jörg M ^e  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

Children; government; industry; psychopharmacology

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CLOMIPRAMINE; LITHIUM; LORAZEPAM; METHYLPHENIDATE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGRANULOCYTOSIS; ATTENTION DEFICIT DISORDER; AUTISM; CHILD PSYCHIATRY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; GILLES DE LA TOURETTE SYNDROME; HUMAN; LIVER TOXICITY; MAJOR DEPRESSION; MEDICAL RESEARCH; MENTAL DISEASE; NEUROSCIENCE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PROGNOSIS; PSYCHOPHARMACOLOGY; REVIEW; SEIZURE; SOCIAL PSYCHOLOGY; SUDDEN DEATH; SUICIDAL BEHAVIOR;

ADOLESCENT; ADOLESCENT PSYCHOLOGY; BIOMEDICAL RESEARCH; CHILD; CHILD BEHAVIOR DISORDERS; CHILD PSYCHOLOGY; CHILD, PRESCHOOL; COOPERATIVE BEHAVIOR; DRUG EVALUATION; DRUG INDUSTRY; FINANCING, GOVERNMENT; FORECASTING; HUMANS; INTERINSTITUTIONAL RELATIONS; PRIVATE SECTOR; PSYCHOPHARMACOLOGY; RESEARCH SUPPORT; UNITED STATES; UNIVERSITIES;

EID: 3042606453     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2004.03.011     Document Type: Review

References (60)

1. Als-Nielsen B., Chen W., Gluud C., Kjaergard L.L. Association of funding and conclusions in randomized drug trials. JAMA. 290:2003;921-928
2. Bekelman J.E., Li Y., Gross C.P. Scope and impact of financial interest in biomedical research. JAMA. 289:2003;454-465
3. Biederman J., Heiligenstein J.H., Faries D.E., Galil N., Dittmann R., Emslie G.J., et al. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics. 110:2002;e75
4. Bodenheimer T. Uneasy alliance - Clinical investigators and the pharmaceutical industry. N Engl J Med. 342:2000;1539-1544
5. Bradley C. The behavior of children receiving Benzedrine. Am J Psychiatry. 94:1937;577-585
6. DeVeaugh-Geiss J., Moroz G., Biederman J., Cantwell D., Fontaine R., Greist J.H., et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder - A multicenter trial. J Am Acad Child Adolesc Psychiatry. 31:1992;45-49
7. DeVeaugh-Geiss J. Academic medical center/industry collaborations. Arch Gen Psychiatry. 48:1991;754-756
8. Emslie G.J., Rush A.J., Weinberg W.A., Kowatch R.A., Hughes C.W., Carmody T., et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 54:1997;1031-1037
9. Emslie G.J., Heiligenstein J.H., Wagner K.D., Hoog S.L., Ernest D.E., Brown E., et al. Fluoxetine for acute treatment of depression in children and adolescents A placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 41:2002;1205-1215
10. European Parliament. Regulation on orphan medicinal products enters into force. Regulation No. 141/2000. Official Journal of the European Communities. 2000;. January 22, 2000. Available at: http://pharmacos.eudra.org/F2/orphanmp/ index.htm. Accessed March 8, 2004
11. Fegert J.M. Ethical and legal problems in treating schizophrenic patients with neuroleptics during childhood and adolescence. Child Adolesc Psychopharmacol. 8:2003;5
12. Fegert J.M. Moeglichkeiten und Grenzen psychopharmakologischer Forschung im Kindesalter. Nervenheilkd. 2:2003;60-65
13. Flament M.F., Rapoport J.L., Berg C.J., Sceery W., Kilts C., Mellstrom B., et al. Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Arch Gen Psychiatry. 42:1985;977-983
14. Food and Drug Administration. Psychopharmacologic drugs advisory committee and the anti-infective drugs advisory committee. February 2, 2004. Briefing information. 2004;. Available at: http://www.fda.gov/ohrms/dockets/ac/ 04/briefing/4006b1.htm. Accessed March 8, 2004
15. Food and Drug Administration. Approved moieties to which FDA has issued a written request for pediatric studies under section 505A of the Federal Food, Drug and Cosmetic Act. 2003;. Available at: http://www.fda.gov/cder/pediatric/ wrstats.htm. Accessed March 8, 2004
16. Food and Drug Administration. Approved moieties to which FDA has granted pediatric exclusivity for pediatric studies under section 505A of the Federal Food, Drug and Cosmetic Act. 2003;. Available at: http://www.fda.gov/cder/ pediatric/exgrant.htm. Accessed March 8, 2004
17. Food and Drug Administration. FDA public health advisory Reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder (MDD). 2003;. October 27, 2003. Available at: http://www.fda.gov/cder/drug/advisory/mdd.htm. Accessed March 8, 2004
18. Food and Drug Administration (1997): Federal Food, Drug and Cosmetic Act (as amended by the FDA Modernization Act of 1997 - Subchapter B: Drugs for rare diseases or conditions (revised November 1, 1999). Available at: http://www.fda.gov/opacom/laws/fdcact/fdcact5b.htm. Accessed March 8, 2004
19. Gastfriend D.R., Biederman J., Jellinek M.S. Desipramine in the treatment of adolescents with attention deficit disorder. Am J Psychiatry. 141:1984;906-908
20. Greenhill L.L., Vitiello B., Abikoff H., Levine J., March J.S., Riddle M.A., et al. Developing methodologies for monitoring long-term safety of psychotropic medications in children Report on the NIMH conference, September 25, 2000. J Am Acad Child Adolesc Psychiatry. 42:2003;651-655
21. ADHD Study Group, Greenhill L.L., Findling R.L., Swanson J.M. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 109:2001;e39
22. Insel T.R., Charney D.S. Research on major depression Strategies and priorities. JAMA. 289:2003;3167-3168
23. James R.S., Sharp W.S., Bastain T.M., Lee P.P., Walter J.M., Czarnolewski M., et al. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiatry. 40:2001;1268-1276
24. Jensen P.S., Bhatara V.S., Vitiello B., Hoagwood K., Feil M., Burke L.B. Psychoactive medication prescribing practices for U.S. children Gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry. 38:1999;557-565
25. Keller M.B., Ryan N.D., Strober M., Klein R.G., Kutcher S.P., Birmaher B., et al. Efficacy of paroxetine in the treatment of adolescent major depression A randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 40:2001;762-772
26. Kowatch R.A., Suppes T., Carmody T.J., Bucci J.P., Hume J.H., Kromelis M., et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 39:2000;713-720
27. Kraemer H.C., Wilson G.T., Fairburn C.G., Agras W.S. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry. 59:2002;877-883
28. Kratochvil C.J., Heiligenstein J.H., Dittmann R., Spencer T.J., Biederman J., Wernicke J., et al. Atomoxetine and methylphenidate treatment in children with ADHD A prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 41:2002;776-784
29. Lebowitz B.D., Vitiello B., Norquist G.S. Approaches to multisite clinical trials The National Institute of Mental Health perspective. Schizophr Bull. 29:2003;7-13
30. Lexchin J., Bero L.A., Djulbegovic B., Clark O. Pharmaceutical industry sponsorship and research outcome and quality Systematic review. BMJ. 326:2003;1-10
31. March J.S., Biederman J., Wolkow R., Safferman A., Mardekian J., Cook E.H., et al. Sertraline in children and adolescents with obsessive-compulsive disorder A multicenter randomized controlled trial. JAMA. 280:1998;1752-1756
32. Melander H., Ahlqvist-Rastad J., Meijer G., Beermann B. Evidence b(i)ased medicine - Selective reporting from studies sponsored by pharmaceutical industry Review of studies in new drug applications. BMJ. 326:2003;1171-1173
33. Michelson D., Faries D., Wernicke J., Kelsey D., Kendrick K., Sallee F.R., et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder A randomized, placebo-controlled, dose-response study. Pediatrics. 108:2001;e83
34. Morin K., Rakatansky H., Riddick F.A. Jr, Morse L.J., O'Bannon J.M. III, Goldrich M.S., et al. Managing conflicts of interest in the conduct of clinical trials. JAMA. 287:2002;78-84
35. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder (ADHD). Arch Gen Psychiatry. 56:1999;1073-1086
36. National Institutes of Health (2003a): Developmental psychopharmacology. NIH guide for grants and contracts, PA-03-113, April 21, 2003, PAR-04-009. Available at: http://grants1.nih.gov/grants/guide/pa-files/PA-03-113.html. Accessed March 8, 2004
37. National Institutes of Health (2003b): Final NIH statement on sharing research data. NIH guide for grants and contracts, February 26, 2003, NOT-OD-03-032. Available at: http://grants2.nih.gov/grants/guide/notice-files/ NOT-OD-03-032.html. Accessed March 8, 2004
38. National Institutes of Health (2003c): National cooperative drug discovery groups for the treatment of mood disorders or nicotine addiction. NIH guide for grants and contracts, October 16, 2003, PAR-04-009. Available at: http://grants1.nih.gov/grants/guide/pa-files/PAR-04-009.html. Accessed March 8, 2004
39. National Institute of Mental Health (2003): Clinical trials. Available at: http://www.nimh.nih.gov/studies/index.cfm. Accessed March 8, 2004
40. National Institute of Mental Health (2001): Pharmacological agents and drugs for mental disorders. NIH guide for grants and contracts, December 4, 2001, PA-02-027. Available at: http://grants1.nih.gov/grants/guide/pa-files/PA- 02-027.html. Access March 8, 2004
41. Olfson M., Marcus S.C., Weissman M.M., Jensen P.S. National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry. 41:2002;514-521
42. Pharmaceutical Research and Manufacturers of America (2002): PhRMA principles on conduct of clinical trials and communication of clinical trial results. Available at: http://www phrma org/publications/policy/2002-06-24 430.pdf. Accessed March 8, 2004
43. Psaty B.M., Rennie D. Stopping medical research to save money - A broken pact with researchers and patients. JAMA. 289:2003;2128-2131
44. Riddle M.A., Kastelic E.A., Frosch E. Pediatric psychopharmacology. J Child Psychol Psychiatry. 42:2001;73-90
45. RUPP Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med. 344:2001;1279-1285
46. RUPP Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 347:2002;314-321
47. Sallee F.R., Kurlan R., Goetz C.G., Singer H., Scahill L., Law G., et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome A pilot study. J Am Acad Child Adolesc Psychiatry. 39:2000;292-299
48. Spencer T., Biederman J., Wilens T., Prince J., Hatch M., Jones J., et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 155:1998;693-695
49. Treatment for Adolescents with Depression Study Team. Treatment for adolescents with depression study (TADS) Rationale, design, and methods. J Am Acad Child Adolesc Psychiatry. 42:2003;531-542
50. United States Congress (1980): Government Patent Policy Act of 1980. Public L No. 96-517
51. United States Congress (1997): Food and Drug Administration Modernization Act. Public L No. 105-115
52. United States Congress (2002): Best Pharmaceuticals for Children Act (BPCA). Public L No. 107-109
53. United States Congress (2003): Pediatric Research Equity Act of 2003. Public L No. 108-155
54. Vitiello B. Ethical considerations in psychopharmacological research involving children and adolescents. Psychopharmacology (Berl). 171:2003;86-91
55. Vitiello B., Jensen P.S. Medication development and testing in children and adolescents. Arch Gen Psychiatry. 54:1997;871-876
56. Vitiello B., Behar D., Malone R., Ryan P., Delaney M.A., Simpson G.M. Pharmacokinetics of lithium carbonate in children. J Clin Psychopharmacol. 8:1988;355-359
57. Wagner K.D., Ambrosini P., Rynn M., Wohlberg C., Yang R., Greenbaum M.S., et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder Two randomized controlled trials. JAMA. 290:2003;1033-1041
58. Wolraich M.L., Greenhill L.L., Pelham W., Swanson J., Wilens T., Palumbo D., et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 108:2001;883-892
59. Zito J.M., Safer D.J., dosReis S., Magder L.S., Gardner J.F., Zarin D.A. Psychotherapeutic medication patterns for youths with attention-deficit/ hyperactivity disorder. Arch Pediatr Adolesc Med. 153:1999;1257-1263
60. Zerhouni E. The NIH roadmap. Science. 302:2003;63-72